ArticleOncotarget2017
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- The Many Roads from Alternative Splicing to Cancer: Molecular Mechanisms Involving Driver Genes.Cancers · 2024Review
- Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer.World journal of clinical oncology · 2024Article
- Ferroptosis-Related lncRNA to Predict the Clinical Outcomes and Molecular Characteristics of Kidney Renal Papillary Cell Carcinoma.Current issues in molecular biology · 2024Article
- Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.Frontiers in medicine · 2024Article
- Quantification of ferroptosis pattern in bladder carcinoma and its significance on immunotherapy.Scientific reports · 2022Article
- A ferroptosis-related gene signature associated with immune landscape and therapeutic response in osteosarcoma.Frontiers in oncology · 2022Article
- Ferroptosis-related gene signature predicts prognosis in kidney renal papillary cell carcinoma.Frontiers in oncology · 2022Article
- Focal Point of Fanconi Anemia Signaling.International journal of molecular sciences · 2021Review
- A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.BMC cancer · 2021Article
- A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.Frontiers in oncology · 2021Article
- Prognostic Model and Nomogram Construction Based on a Novel Ferroptosis-Related Gene Signature in Lower-Grade Glioma.Frontiers in genetics · 2021Article
- Article
- Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.Biomolecules · 2020Review
- Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression.Frontiers in cell and developmental biology · 2020Article
- Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.Scientific reports · 2019Article
- A new look at molecular biology of breast cancer.Cancer biology & therapy · 2019Review
- Multifaceted Fanconi Anemia Signaling.Trends in genetics : TIG · 2018Review
- DNA methylation at the vicinity of the proximal polyadenylation site in FANCD2 gene involves human malignancy.Cell cycle (Georgetown, Tex.) · 2018Article
- Fanconi Anemia Signaling and Cancer.Trends in cancer · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Fanconi Anemia (FA) complementation group D2 protein (FANCD2) is the center of the FA tumor suppressor pathway, which has become an important field of investigation in human aging and cancer. Here we report an overlooked central player in the FA pathway, FANCD2 variant 2 (FANCD2-V2), which appears to perform more potent tumor suppressor-function compared to the known variant of FANCD2, namely, FANCD2-V1. Detailed analysis of the FANCD2 gene structure indicated a proximal and distal polyadenylation site (PAS), associated with V2 and V1 transcripts accordingly. RNA polymerase II Chromatin immunoprecipitation (ChIP) targeting the two PAS-regions determined lesser binding of RNA pol II to DNA fragments in the distal PAS region in non-malignant cells compared to malignant cells. Conversely, the opposite occurred in the proximal PAS region. Moreover, RNA immunoprecipitation (RIP) identified that U2 snRNP, a major component of RNA splicing complex that interacts with the 3'end of an intron, showed greater binding to the last intron of the FANCD2-V1 transcript in malignant cells compared to the non-malignant cells. Importantly, our data showed that in human tissue samples, the ratio of V2 /V1 expression in lung, bladder, or ovarian cancer correlates inversely with the tumor stages/grades. Therefore, these findings provide a previously unrecognized central player FANCD2-V2 and thus novel insights into human tumorigenesis, and indicate that V2/V1 can act as an effective biomarker in assisting the recognition of tumor malignance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.